Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma

AIDS Research and Human Retroviruses

Volumn 15, Issue 13, 1999, Pages 1191-1200

  Vázquez Rosales, Guillermo ^a   García Lerma, J Gerardo ^a   Yamamoto, Shinji ^a   Switzer, William M ^a   Havlir, Diane ^b   Folks, Thomas M ^a   Richman, Douglas D ^b   Heneine, Walid ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; EFAVIRENZ; LOVIRIDE; NEVIRAPINE; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SCREENING; EARLY DIAGNOSIS; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; VIRUS DETECTION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CODON; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTATION; NEVIRAPINE; PLAQUE ASSAY; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRUS CULTIVATION;

EID: 2442770033     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310287     Document Type: Article

References (36)

1. Koup RA, Merluzzi VJ, Hargrave KD, et al.: Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991;163:966-970.
2. Maga G, Amacker M, Ruel N, Hubscher U, and Spadari S: Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1977;274:738-747.
3. Spence RA, Kati WM, Anderson KS, and Johnson KA: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995;267:988-993.
4. Cheeseman SH, Havlir D, Laughlin MM, et al.: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:141-151.
5. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. JAMA 1997;277:1962-1969.
6. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996; 124:1019-1030.
7. Kaspar R, Werntz G, and DuBois DB: Early results of combined stavudine, lamivudine, and nevirapine: a twice daily, well-tolerated, protease inhibitor-sparring regimen for the treatment of HIV-1 infection. In: Program and Abstracts of the 5th Conference of Retroviruses and Opportunistic Infections, Chicago, Illinois. Foundation for Retrovirology and Human Health, Alexandria, VA, 1998, p. 209. [Abstract 696]
8. Luzuriaga K, Bryson Y, Krogstad P, et al.: Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997; 336:1343-1349.
9. Montaner JSG, Reiss P, Cooper D, et al.: A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA 1998;279:930-937.
10. Mirochnick M, Fenton T, Gangier P, et al.: Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998;178:368-374.
11. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995;172:1379-1383.
12. Hirsch MS, Conway B, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998;279: 1984-1991.
13. Richman D, Shih CK, Lowy I, et al.: Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci USA 1991; 88:11241-11245.
14. Havlir D, Eastman S, Gamst A, and Richman DD: Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. J Virol 1996;70:7894-7899.
15. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666.
16. Jellinger RM, Shafer RW, and Merigan TC: A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. J Infect Dis 1997;175:561-566.
17. Kusumi K, Conway B, Cunningham S, et al.: Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol 1992;66:875-885.
18. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, and Hahn BH: Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: Identification of replication-competent and -defective viral genomes. J Virol 1991;65:3973-3985.
19. Kellam P and Larder BA: Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994;38:23-30.
20. Hertogs K, Bethune MD, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-276.
21. Jong MD, Vella S, Carr A, et al.: High-dose nevirapine in previously untreated human immunodeficiency virus type-1 infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-970.
22. Kuritzkes DR: Clinical significance of drug resistance in HIV-1 infection. AIDS 1996;10(Suppl. 5):S27-S31.
23. Heneine W, Yamamoto S, Switzer WM, Spira TJ, and Folks TM: Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. J Infect Dis 1995;171:1210-1216.
24. Yamamoto S, Folks TM, and Heneine W: Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: Optimization, validation, and comparative analysis with other detection systems. J Virol Methods 1996;61:135-143.
25. Garcia Lerma JG, Yamamoto S, Gomez-Cano M, et al.: Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: Evidence of variabilities in levels of virion-associated RT. J Infect Dis 1998; 177: 1221-1229.
26. Shafer RW, Iversen AKN, Winters MA, et al.: Drug resistance and heterogeneous long-term virologie responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J Infect Dis 1995;172:70-78.
27. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, and Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32: 292-300.
28. Vandamme AM, Witvrouw M, Pannecouque C, et al.: Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Methods in Molecular Medicine: Antiviral Chemotherapy Protocols (Kinchington J and Schinazi RF, eds.). Humana Press, Totowa, New Jersey 1998 (in press).
29. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine. Science 1989;246:1155-1158.
30. Larder BA, Kellam P, and Kemp SD: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature (London) 1993;365:451-453.
31. Schinazi RF, Lloyd RM, Nguyen MH, et al.: Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881.
32. Ueno T, Shirasaka T, and Mitsuya H: Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem 1995;270:23605-23611.
33. Imrie A, Beveridge A, Genn W, et al.: Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. J Infect Dis 1997;175:1502-1506.
34. Schinazi RF, Larder BA, and Mellors JW: Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5: 129-142.
35. Jeffrey S, Baker D, Tritch R, Rizzo C, Logue K, and Bacheler L: A resistance and cross-resistance profiles for SUSTIVA (efavirenz, DMP 266). In: Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic infections, Chicago, Illinois 1998. Foundation for Retrovirology and Human Health, Alexandria, VA, 1998, p. 210. [Abstract 702]
36. Garcia Lerma JG, Schinazi RF, Juodawlkis AS, et al.: A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamiructirie (3TC). Antimicrob Agents Chemother 1999;43:264-270.